ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (Nasdaq: XTLB; TASE: XTL).
Some of the statements included in this press release, particularly
those anticipating the continued uninterrupted trading of the Company's
ADRs on the NASDAQ Capital Market and the Company's ability to maintain
compliance with NASDAQ Capital Market listing requirements, may be
forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the safe
harbor for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. Risk factors that could adversely affect our
operations are identified from time to time in our reports filed with
Securities and Exchange Commission, including our annual report on Form
20-F filed with the Securities and Exchange Commission on March 27, 2008.
Any forward-looking statements set forth in this press release speak only
as of the date of this press release. We do not intend to update any of
these forward-looking statements to reflect events or circumstances that
occur after the dat
|SOURCE XTL Biopharmaceuticals Ltd.|
Copyright©2008 PR Newswire.
All rights reserved